{
  "meta": {
    "title": "00245_Mid_Day_Module_Medicine-1",
    "url": "https://brainandscalpel.vercel.app/00245-mid-day-module-medicine-1-4012f37e.html",
    "scrapedAt": "2025-11-29T18:14:41.644Z"
  },
  "questions": [
    {
      "id": 53809,
      "choices": [
        {
          "id": 214709,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Activates a GPCR increasing cAMP. </span></span></span></p>"
        },
        {
          "id": 214710,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Directly activates PKC. </span></span></span></p>"
        },
        {
          "id": 214711,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Binds nuclear receptor. </span></span></span></p>"
        },
        {
          "id": 214712,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Interacts with tyrosine kinase receptor.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 30-year-old woman presents with complaints of polyuria (excessive urination), polydipsia (excessive thirst), and fatigue. Laboratory results reveal hyperglycemia and glucosuria. Which of the following best describes the mechanism of action of the hormone likely deficient in this patient?</span></span></span></p>",
      "unique_key": "Q5509148",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368705,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Interacts with tyrosine kinase receptor.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s symptoms are classic for diabetes mellitus, a condition characterized by insulin deficiency or resistance. Insulin is a peptide hormone (Group II) that binds to tyrosine kinase receptors on target cells. This binding triggers autophosphorylation of the receptor and subsequent activation of intracellular signaling cascades, leading to increased glucose uptake and utilization.<strong> </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Activates a GPCR increasing cAMP:</span></strong><span style=\"font-size:12.0pt\"> This mechanism is characteristic of some Group II hormones (e.g., glucagon), but not insulin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Directly activates PKC:</span></strong><span style=\"font-size:12.0pt\"> While PKC activation can occur downstream of insulin signaling, it is not the primary mechanism of action.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Binds nuclear receptor:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This mechanism is characteristic of Group I hormones (e.g., steroid hormones, thyroid hormones)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin interacts with tyrosine kinase receptors on target cells to mediate its effects.</span></span></span></p>",
      "correct_choice_id": 214712,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53849,
      "choices": [
        {
          "id": 214869,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Falsely low PRL levels can be due to macroprolactinemia.</span></span></span></p>"
        },
        {
          "id": 214870,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hook effect causes falsely elevated values of prolactin.</span></span></span></p>"
        },
        {
          "id": 214871,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Most common symptom in women is galactorrhea.</span></span></span></p>"
        },
        {
          "id": 214872,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Can be associated with reduced Bone Mineral Density.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is true regarding hyperprolactinemia?</span></span></p>",
      "unique_key": "Q9161599",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368728,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Can be associated with reduced Bone Mineral Density</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic hyperprolactinemia can reduce vertebral bone mineral density due to hypogonadism (since PRL suppresses GnRH release </span><span style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&agrave;</span></span><span style=\"font-size:12.0pt\"> it results in low FSH/LH and subsequent hypoestrogenism). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Falsely low PRL levels can be due to</span></strong><span style=\"font-size:12.0pt\"> <strong>macroprolactinemia</strong>: Macroprolactinemia is caused by aggregated forms of circulating PRL, which are usually biologically inactive. This can result in falsely increased PRL values.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hook effect causes falsely elevated values of prolactin:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Markedly elevated PRL levels (&gt;1000 &mu;g/L), can result in falsely low PRL values because of assay artifacts (the hook effect). Sample dilution is required to measure these high values accurately<strong> </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Most common symptom in women is galactorrhea:</span></strong><span style=\"font-size:12.0pt\"> Most common symptom in women is gonadal dysfunction (galctorrhea occurs in </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 80% women)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic hyperprolactinemia can reduce vertebral bone mineral density due to hypogonadism caused by prolactin suppressing GnRH release, resulting in low FSH/LH and subsequent hypoestrogenism.</span></span></span></p>",
      "correct_choice_id": 214872,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19984,
      "choices": [
        {
          "id": 79897,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GATA6 mutations </span></span></span></p>"
        },
        {
          "id": 79898,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucokinase mutations </span></span></span></p>"
        },
        {
          "id": 79899,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ABCC8 activating mutations </span></span></span></p>"
        },
        {
          "id": 79900,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mtDNA mutations</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the most common cause of pancreatic agenesis?</span></span></p>",
      "unique_key": "Q5270252",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368698,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) GATA6 mutations</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GATA6 is a transcription factor essential for pancreatic development. Mutations in the GATA6 gene are the most common known genetic cause of pancreatic agenesis, a condition where the pancreas fails to develop during embryogenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Glucokinase mutations:</span></strong><span style=\"font-size:12.0pt\"> Heterozygous mutations are associated with maturity-onset diabetes of the young (MODY) type 2, characterized by mild, stable hyperglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Homozygous mutations are associated with severe neonatal diabetes.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. ABCC8 activating mutations:</span></strong><span style=\"font-size:12.0pt\"> These mutations cause a form of neonatal diabetes that can be treated with sulfonylureas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. mtDNA mutations:</span></strong><span style=\"font-size:12.0pt\"> Mutations in mitochondrial DNA can cause a rare form of diabetes associated with deafness, but not typically pancreatic agenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GATA6 mutations are the most common cause of pancreatic agenesis.</span></span></span></p>",
      "correct_choice_id": 79897,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20096,
      "choices": [
        {
          "id": 80345,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Repeat fasting blood sugar (FBS) for 3 days </span></span></span></p>"
        },
        {
          "id": 80346,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Do a 3 AM blood glucose check </span></span></span></p>"
        },
        {
          "id": 80347,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase evening/night time insulin dose </span></span></span></p>"
        },
        {
          "id": 80348,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduce carbohydrate intake in meals</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old man with type 1 diabetes on insulin therapy reports waking up with high blood glucose levels despite going to bed with normal readings. Which of the following would be most helpful in determining the cause of the morning hyperglycemia?</span></span></span></p>",
      "unique_key": "Q5290658",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368690,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Do a 3 AM blood glucose check</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s symptoms could be due to either the Somogyi effect or the dawn phenomenon:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Somogyi effect:</span></strong><span style=\"font-size:12.0pt\"> Nocturnal hypoglycemia triggers a counter-regulatory hormone release, leading to rebound hyperglycemia in the morning.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Dawn phenomenon:</span></strong><span style=\"font-size:12.0pt\"> Normal hormonal changes in the early morning hours lead to increased insulin resistance and elevated blood glucose.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 3 AM blood glucose check can help differentiate between these two conditions:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Hypoglycemia at 3 AM:</span></strong><span style=\"font-size:12.0pt\"> Suggests the Somogyi effect.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Normal or elevated glucose at 3 AM:</span></strong><span style=\"font-size:12.0pt\"> Suggests the dawn phenomenon.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Identifying the underlying cause is crucial for appropriate treatment adjustments.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Repeat FBS for 3 days:</span></strong><span style=\"font-size:12.0pt\"> While useful for assessing overall glycemic control, it won&#39;t pinpoint the cause of the morning hyperglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increase evening/night time insulin dose:</span></strong><span style=\"font-size:12.0pt\"> This might be appropriate if the dawn phenomenon is confirmed, but it could worsen hypoglycemia if the Somogyi effect is the cause.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Reduce carbohydrate intake in meals:</span></strong><span style=\"font-size:12.0pt\"> This could help manage overall blood sugar levels but may not address the specific issue of morning hyperglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 3 AM blood glucose check helps differentiate between the Somogyi effect (nocturnal hypoglycemia) and the dawn phenomenon (early morning insulin resistance).</span></span></span></p>",
      "correct_choice_id": 80346,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53899,
      "choices": [
        {
          "id": 215069,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alzheimer&rsquo;s disease </span></span></span></p>"
        },
        {
          "id": 215070,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gout </span></span></span></p>"
        },
        {
          "id": 215071,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-alcoholic fatty liver disease </span></span></span></p>"
        },
        {
          "id": 215072,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Polycystic ovarian syndrome</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with metabolic syndrome are at higher risk for all of the following EXCEPT:</span></span></span></p>",
      "unique_key": "Q1303613",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368694,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Alzheimer&#39;s disease</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While there is some evidence suggesting a potential link between metabolic syndrome and an increased risk of Alzheimer&#39;s disease, the association is not as strong or well-established as the link between metabolic syndrome and the other options listed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Gout:</span></strong><span style=\"font-size:12.0pt\"> The metabolic syndrome is associated with increased uric acid levels, a key risk factor for gout.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Nonalcoholic fatty liver disease (NAFLD):</span></strong><span style=\"font-size:12.0pt\"> Insulin resistance, a central feature of metabolic syndrome, is strongly linked to the development of NAFLD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Polycystic ovarian syndrome (PCOS):</span></strong><span style=\"font-size:12.0pt\"> Insulin resistance is also a key factor in the development of PCOS, and metabolic syndrome is frequently seen in women with PCOS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metabolic syndrome is linked with gout, non-alcoholic fatty liver disease, and polycystic ovarian syndrome but not strongly with Alzheimer&#39;s disease.</span></span></span></p>",
      "correct_choice_id": 215069,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53813,
      "choices": [
        {
          "id": 214725,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoid receptor (GR) </span></span></span></p>"
        },
        {
          "id": 214726,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thyroid hormone receptor (TR) </span></span></span></p>"
        },
        {
          "id": 214727,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vitamin D receptor (VDR) </span></span></span></p>"
        },
        {
          "id": 214728,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Retinoic acid receptor (RAR)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following steroid receptors primarily functions as a homodimer upon ligand binding?</span></span></p>",
      "unique_key": "Q3343886",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368709,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. A) Glucocorticoid receptor (GR)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoid receptors (GRs) typically form homodimers upon binding to their ligand (cortisol). This homodimer then translocates to the nucleus, where it binds to specific DNA sequences called glucocorticoid response elements (GREs) to regulate gene expression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Thyroid hormone receptor (TR):</span></strong><span style=\"font-size:12.0pt\"> TRs typically form heterodimers with retinoid X receptors (RXRs).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Vitamin D receptor (VDR):</span></strong><span style=\"font-size:12.0pt\"> VDRs also primarily form heterodimers with RXRs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Retinoic acid receptor (RAR):</span></strong><span style=\"font-size:12.0pt\"> RARs predominantly form heterodimers with RXRs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Homodimer (Steroid) Receptors - ER, AR, PR, GR</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cytoplasmic in location. Translocates to nucleus after binding to a ligand (also called as type 1 nuclear receptors)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ligands usually induce coactivator binding</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heterodimer Receptors - TR, VDR, RAR, PPAR</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nuclear in location (also called as type 2 nuclear receptors)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ligand dissociates corepressors and induces coactivator binding</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Orphan Receptors - SF-1, DAX-1, HNF4&alpha;</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nuclear in location and they do not have known agonists (bind to nuclear intermediates)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Action may be ligand independent &amp; can be homo-dimeric or hetero-dimeric</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-152909.png\" style=\"height:339px; width:500px\" /></span></span></span></p>",
      "correct_choice_id": 214725,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53931,
      "choices": [
        {
          "id": 215193,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glycemic index </span></span></span></p>"
        },
        {
          "id": 215194,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glycemic load </span></span></span></p>"
        },
        {
          "id": 215195,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin to carbohydrate ratio </span></span></span></p>"
        },
        {
          "id": 215196,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Preprandial blood glucose values</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is essential for calculating insulin dose prior to a meal in type 1 diabetics?</span></span></p>",
      "unique_key": "Q6633971",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368704,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Insulin to carbohydrate ratio</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The insulin to carbohydrate ratio (I:C ratio) is the most essential factor for calculating the insulin dose for a meal in type 1 diabetes. It represents the number of grams of carbohydrates covered by one unit of insulin. By knowing the I:C ratio and the amount of carbohydrates in a meal, the patient can calculate the appropriate insulin dose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Glycemic index:</span></strong><span style=\"font-size:12.0pt\"> While the glycemic index provides information about how quickly a food raises blood sugar, it is not directly used in calculating the insulin dose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Glycemic load:</span></strong><span style=\"font-size:12.0pt\"> Glycemic load combines the glycemic index with the amount of carbohydrate in a food. It can be helpful in meal planning, but the I:C ratio is the primary tool for calculating the insulin dose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Preprandial blood glucose values:</span></strong><span style=\"font-size:12.0pt\"> While important for determining the need for a correction dose of insulin, preprandial blood glucose values alone are not sufficient to calculate the mealtime insulin dose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The insulin to carbohydrate ratio is essential for calculating the insulin dose for a meal in type 1 diabetes.</span></span></span></p>",
      "correct_choice_id": 215195,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53853,
      "choices": [
        {
          "id": 214885,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Octreotide </span></span></span></p>"
        },
        {
          "id": 214886,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Lanreotide </span></span></span></p>"
        },
        {
          "id": 214887,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Pegvisomant </span></span></span></p>"
        },
        {
          "id": 214888,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pasireotide</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 48-year-old woman with acromegaly is currently being treated with a drug but her growth hormone (GH) levels remain paradoxically elevated. Which of the following medications is she most likely taking?</span></span></p>",
      "unique_key": "Q4047374",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368730,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Pegvisomant</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pegvisomant is a GH receptor antagonist. It works by blocking the action of GH at its receptor, thereby reducing IGF-1 production and effectively treating the symptoms of acromegaly. However, it increases GH resistance and hence, GH levels may remain elevated. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Octreotide and Option B. Lanreotide:&nbsp;</span></strong><span style=\"font-size:12.0pt\">SRLs (somatostatin receptor ligand)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduces GH and IGF-1 levels and reduces pituitary tumor size in ~50% of patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All SRLs can cause GI side effects, glucose intolerance (or diabetes), cholesterol gall stones, asymptomatic bradycardia and hypothyroxinemia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Octreotide is available as LAR and oral forms. Lanreotide is available as slow release depot formulation. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pasireotide:</span></strong><span style=\"font-size:12.0pt\"> SRL specific for SST5 &ndash; can be used if resistant to octreotide or lanreotide. Higher prevalence of glucose intolerance and diabetes. Available as LAR.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pegvisomant, a GH receptor antagonist, can cause paradoxically elevated GH levels despite reducing IGF-1 production and treating symptoms of acromegaly.</span></span></span></p>",
      "correct_choice_id": 214887,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53846,
      "choices": [
        {
          "id": 214857,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Surgical resection</span></span></span></p>"
        },
        {
          "id": 214858,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Radiotherapy </span></span></span></p>"
        },
        {
          "id": 214859,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GnRH analogs </span></span></span></p>"
        },
        {
          "id": 214860,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACTH</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 4-year-old child presents with precocious puberty, psychomotor delay, and laughing seizures. What is the first-line treatment?</span></span></p>",
      "unique_key": "Q1672044",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368724,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) GnRH analogs</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The symptoms suggest hypothalamic hamartoma, a benign tumor associated with a typical triad of&nbsp; precocious puberty, psychomotor delay, and gelastic (laughing) seizures. GnRH analogs suppress the HPG axis, halting precocious puberty.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Surgical resection:</span></strong><span style=\"font-size:12.0pt\"> Reserved for severe or refractory cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Radiotherapy:</span></strong><span style=\"font-size:12.0pt\"> Not preferred in children due to long-term side effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. ACTH:</span></strong><span style=\"font-size:12.0pt\"> Not relevant to precocious puberty treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GnRH analogs are the first-line treatment for precocious puberty associated with hypothalamic hamartoma.</span></span></span></p>",
      "correct_choice_id": 214859,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53909,
      "choices": [
        {
          "id": 215105,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pharmacotherapy </span></span></span></p>"
        },
        {
          "id": 215106,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bariatric surgery</span></span></span></p>"
        },
        {
          "id": 215107,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diet, exercise, and behavioral therapy </span></span></span></p>"
        },
        {
          "id": 215108,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No intervention needed</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32-year-old woman with a BMI of 31 kg/m&sup2; and no obesity-related comorbidities is seeking advice on weight management. What is the most appropriate initial intervention for this patient?</span></span></p>",
      "unique_key": "Q5070152",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368703,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Diet, exercise, and behavioral therapy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A BMI of 31 kg/m&sup2; falls into the obesity class I category. The most appropriate initial intervention for individuals with obesity class I and no comorbidities is lifestyle modification, which includes diet, exercise, and behavioral therapy. These interventions aim to create a calorie deficit and promote sustainable weight loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pharmacotherapy:</span></strong><span style=\"font-size:12.0pt\"> While pharmacotherapy can be an adjunct to lifestyle modification for weight loss, it is not the first-line treatment for patients with obesity class I without comorbidities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Bariatric surgery:</span></strong><span style=\"font-size:12.0pt\"> Bariatric surgery is reserved for patients with severe obesity (BMI &ge; 40 kg/m&sup2;) or those with BMI &ge; 35 kg/m&sup2; and significant comorbidities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. No intervention needed:</span></strong><span style=\"font-size:12.0pt\"> Although the patient does not have any current comorbidities, a BMI of 31 kg/m&sup2; puts her at risk for developing obesity-related health problems in the future. Therefore, intervention is recommended to prevent these complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-104442.png\" style=\"height:269px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The initial intervention for patients with class I obesity without comorbidities should be diet, exercise, and behavioral therapy.</span></span></span></p>",
      "correct_choice_id": 215107,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53818,
      "choices": [
        {
          "id": 214745,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal adult serum PRL levels are about 10&ndash;25 &micro;g/mL in women </span></span></span></p>"
        },
        {
          "id": 214746,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peak serum PRL levels (up to 30 &micro;g /mL) occur between 4:00 and 6:00 a.m </span></span></span></p>"
        },
        {
          "id": 214747,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Highest secretory peaks occurring during rapid eye movement (REM) sleep </span></span></span></p>"
        },
        {
          "id": 214748,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Circulating half-life of PRL is ~50 min</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are true about Prolactin except:</span></span></p>",
      "unique_key": "Q2966081",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368712,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans. C)</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Highest secretory peaks occurring during rapid eye movement (REM) sleep</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While prolactin levels do increase during sleep, the highest secretory peaks actually occur during the non-REM (NREM) stages, particularly slow-wave sleep. REM sleep is associated with a relative decrease in prolactin secretion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Normal adult serum PRL levels are about 10-25 ng/mL in women:</span></strong><span style=\"font-size:12.0pt\"> This is the typical range for non-pregnant women. Normal serum PRL levels in men are about 10-25 ng/mL. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Peak serum PRL levels (up to 30 &micro;g /mL) occur between 4:00 and 6:00 AM:</span></strong><span style=\"font-size:12.0pt\"> Prolactin levels follow a circadian rhythm, with the highest levels occurring during the early morning hours.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Circulating half-life of PRL is ~50 min:</span></strong><span style=\"font-size:12.0pt\"> Prolactin is relatively quickly cleared from the bloodstream, since it is a polypeptide.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Highest secretory peaks of prolactin occur during non-REM (NREM) sleep, not REM sleep.</span></span></span></p>",
      "correct_choice_id": 214747,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53844,
      "choices": [
        {
          "id": 214849,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Anterior </span></span></span></p>"
        },
        {
          "id": 214850,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Central </span></span></span></p>"
        },
        {
          "id": 214851,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ventromedial </span></span></span></p>"
        },
        {
          "id": 214852,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Posterior</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 16-year-old boy has been diagnosed with craniopharyngioma. He also has hyperphagia and obesity. This is seen in damage to which of the hypothalamic nuclei? </span></span></p>",
      "unique_key": "Q5363827",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368722,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Ventromedial</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperphagia (excessive eating) and obesity are characteristic symptoms of damage to the <strong>ventromedial nucleus (VMN)</strong> of the hypothalamus. The VMN is a key satiety center containing melanocortin receptors and regulated by leptin, insulin and POMC. Damage to this area can lead to a loss of satiety signals, resulting in overeating and obesity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Anterior:</span></strong><span style=\"font-size:12.0pt\"> Lesions result in Paradoxical vasoconstriction, tachycardia, and hyperthermia</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Central:</span></strong><span style=\"font-size:12.0pt\"> Lesions result in Excess sympathetic activity </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Posterior:</span></strong><span style=\"font-size:12.0pt\"> Lesions result in Periodic Hypothermia syndrome</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Damage to the ventromedial nucleus of the hypothalamus leads to hyperphagia and obesity due to loss of satiety signals.</span></span></span></p>",
      "correct_choice_id": 214851,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53858,
      "choices": [
        {
          "id": 214905,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intravenous hypertonic saline (3%) </span></span></span></p>"
        },
        {
          "id": 214906,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fluid restriction </span></span></span></p>"
        },
        {
          "id": 214907,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Demeclocycline </span></span></span></p>"
        },
        {
          "id": 214908,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tolvaptan</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old male smoker presents with mild confusion and nausea. He has a serum sodium of 125 mEq/L and a urine osmolality of 450 mOsm/kg. His BP and JVP are normal. Which of the following is the most appropriate initial treatment for him?</span></span></p>",
      "unique_key": "Q4193613",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368733,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Fluid restriction</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The likely diagnosis is SIADH (history of smoking may suggest a possible small cell lung cancer). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For hyponatremia due to SIADH (without severe symptoms), the initial treatment of choice is fluid restriction. This helps correct hyponatremia by limiting water intake and allowing the body to naturally excrete excess water.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Intravenous hypertonic saline (3%):</span></strong><span style=\"font-size:12.0pt\"> This is reserved for severe hyponatremia (&lt;120 mEq/L) with significant neurological symptoms (coma, seizures)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Demeclocycline:</span></strong><span style=\"font-size:12.0pt\"> This is a tetracycline antibiotic that can be used for chronic SIADH but is not the initial treatment for mild cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tolvaptan:</span></strong><span style=\"font-size:12.0pt\"> This is a vasopressin receptor antagonist used for SIADH, but it is not the first-line treatment for mild cases due to its potential side effects and cost.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fluid restriction is the initial treatment of choice for hyponatremia due to SIADH without severe symptoms.</span></span></span></p>",
      "correct_choice_id": 214906,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53842,
      "choices": [
        {
          "id": 214841,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pituitary adenomas frequently extend in a suprasellar direction. </span></span></span></p>"
        },
        {
          "id": 214842,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Headache is a common feature.</span></span></span></p>"
        },
        {
          "id": 214843,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Headache severity correlates with adenoma size or extension. </span></span></span></p>"
        },
        {
          "id": 214844,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Suprasellar extension can lead to visual loss.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 33-year-old lady presented with headache. MRI revealed a pituitary tumor. All of the following are true except?</span></span></p>",
      "unique_key": "Q6721071",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368721,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Headache severity correlates with adenoma size or extension.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Headaches are common features of small intrasellar tumors, even without suprasellar extension. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Because of the confined nature of the pituitary, small changes in intrasellar pressure stretch the dural plate; however, headache severity correlates poorly with adenoma size or extension.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pituitary adenomas frequently extend in a suprasellar direction:</span></strong><span style=\"font-size:12.0pt\"> Pituitary tumors often grow upwards towards the optic chiasm.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Headache is a common feature:</span></strong><span style=\"font-size:12.0pt\"> Headaches are a frequent symptom of pituitary tumors, often due to pressure effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Suprasellar extension can lead to visual loss:</span></strong><span style=\"font-size:12.0pt\"> Upward growth of a pituitary tumor can compress the optic chiasm, leading to visual field defects or loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Headache severity in pituitary adenomas does not correlate well with tumor size or extension.</span></span></span></p>",
      "correct_choice_id": 214843,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53820,
      "choices": [
        {
          "id": 214753,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic glucocorticoid excess decreases GH release. </span></span></span></p>"
        },
        {
          "id": 214754,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGF-1 inhibits GH. </span></span></span></p>"
        },
        {
          "id": 214755,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH stimulates lipolysis, leading to reduced lean body mass. </span></span></span></p>"
        },
        {
          "id": 214756,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGFBP3 is the major carrier protein for IGF-1.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is false regarding GH and IGF-1?</span></span></p>",
      "unique_key": "Q4099554",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368713,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) GH stimulates lipolysis, leading to reduced lean body mass.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH stimulates lipolysis (breakdown of fats), but this process actually leads to an increase in lean body mass and a decrease in fat mass.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chronic glucocorticoid excess decreases GH release:</span></strong><span style=\"font-size:12.0pt\"> Glucocorticoids can suppress GH secretion and can result in growth failure in children. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. IGF-1 inhibits GH:</span></strong><span style=\"font-size:12.0pt\"> IGF-1, which is produced in response to GH, acts as a negative feedback signal to inhibit further GH release.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. IGFBP3 is the major carrier protein for IGF-1:</span></strong><span style=\"font-size:12.0pt\"> IGFBP3 is the most abundant IGF-binding protein in circulation and plays a crucial role in regulating IGF-1 bioavailability and activity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Summary of GH and IGF-1:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">50% of anterior pituitary cell population is somatotrophs (that secrete GH)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH secretion is pulsatile and highest at night.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH secretion is increased by GHRH, ghrelin and decreased by somatostatin &amp; IGF-1. Chronic glucocorticoid use can suppress GH secretion and can result in growth failure in children. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH secretion declines with age&nbsp; (correlates with age related sarcopenia) and obesity (IGF-1 levels in obesity may be normal)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH induces insulin resistance, protein synthesis, nitrogen retention, lipolysis, and sodium and water retention. GH also promotes linear bone growth.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Most GH effects are mediated indirectly through somatomedins (IGF-1 is the most important somoatomedin).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGF-1 is the major somatomedin and primarily produced in the liver in response to GH. IGF-1 is bound to IGFBPs in circulation (most important is IGFBP3).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGF-1 side effects include hypoglycemia, hypotension, fluid retention, TMJ pain, and increased intracranial pressure and possibly can cause retinal damage and avascular femoral head necrosis. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH stimulates lipolysis, leading to an increase in lean body mass and a decrease in fat mass.</span></span></span></p>",
      "correct_choice_id": 214755,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20081,
      "choices": [
        {
          "id": 80285,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Check ketones </span></span></span></p>"
        },
        {
          "id": 80286,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inject insulin and exercise </span></span></span></p>"
        },
        {
          "id": 80287,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Avoid carbohydrates for the day </span></span></span></p>"
        },
        {
          "id": 80288,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recheck CBG the next day</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 21-year-old professional gym trainer who is a known type 1 diabetic is about to start a training session. Just before the session, he notices his capillary blood glucose (CBG) to be 280 mg/dL. What should he do?</span></span></p>",
      "unique_key": "Q8787013",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368735,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Check ketones</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A CBG of 280 mg/dL indicates significant hyperglycemia, which can be dangerous for people with type 1 diabetes. Before exercising, it is essential to check for ketones. The presence of ketones indicates that the body is breaking down fat for energy due to insufficient insulin, and this can lead to diabetic ketoacidosis (DKA), a serious condition. If ketones are present, the individual should not exercise and seek medical attention immediately.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Glycemic management during exercise:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">CBG &lt; 90 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> Ingest 15 to 30&thinsp;g of glucose before starting exercise. Delay exercise until blood glucose is&nbsp;90&thinsp;mg/dL and monitor closely for hypoglycaemia.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">CBG 90 to 125 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> Ingest 10&thinsp;g of glucose before starting aerobic exercise. Anaerobic exercise and high intensity interval training sessions can be started.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">CBG 126 to 250 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> Aerobic exercise can be started. </span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anaerobic exercise can be started, but glucose concentrations could rise.</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">CBG &gt; 250 mg/dL</span></strong><span style=\"font-size:12.0pt\">: Check ketones. </span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ketones &lt; 0&middot;6&thinsp;mmol/L: Mild-to-moderate aerobic exercise can be started</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ketones 0.6- 1&middot;4&thinsp;mmol/L: Exercise should be restricted to a light intensity for only a brief duration (&lt;30&thinsp;min) and a small corrective insulin dose might be needed. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ketones &ge;1.5&thinsp;mmol/L: Exercise is contraindicated and glucose management should be initiated rapidly as per the advice of the healthcare professional team.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Inject insulin and exercise:</span></strong><span style=\"font-size:12.0pt\"> Injecting insulin before exercise could lead to hypoglycemia during the workout, which can be dangerous.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Avoid carbohydrates for the day:</span></strong><span style=\"font-size:12.0pt\"> This could also lead to hypoglycemia as carbohydrates are the primary source of energy for the body.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Recheck CBG the next day:</span></strong><span style=\"font-size:12.0pt\"> Delaying action on elevated blood sugar levels is not recommended and could lead to complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Check for ketones before exercising if blood glucose levels are above 250 mg/dL to prevent the risk of diabetic ketoacidosis.</span></span></span></p>",
      "correct_choice_id": 80285,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19961,
      "choices": [
        {
          "id": 79805,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GLP1 and GIP reduce insulin secretion. </span></span></span></p>"
        },
        {
          "id": 79806,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Portal to peripheral insulin ratio is 1:1 </span></span></span></p>"
        },
        {
          "id": 79807,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucose &lt; 70 mg/dL shuts off insulin secretion. </span></span></span></p>"
        },
        {
          "id": 79808,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin release from beta cells is glucose independent.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following regarding insulin is correct?</span></span></p>",
      "unique_key": "Q1185668",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368717,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Glucose &lt; 70 mg/dL shuts off insulin secretion.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin secretion is tightly regulated by blood glucose levels. When blood glucose levels fall below a threshold (typically around 70 mg/dL), insulin secretion is suppressed to prevent hypoglycemia. This is a crucial mechanism for maintaining glucose homeostasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. GLP1 and GIP reduce insulin secretion:&nbsp;</span></strong><span style=\"font-size:12.0pt\">GLP1 (Glucagon-like peptide-1) and GIP (Glucose-dependent insulinotropic polypeptide) are incretin hormones that actually <em>increase</em> insulin secretion in response to oral glucose intake.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Portal to peripheral insulin ratio is 1:1:</span></strong><span style=\"font-size:12.0pt\"> The portal to peripheral insulin ratio is approximately 2:1, as a significant portion (50%) of insulin is cleared by the liver in the first pass.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Insulin release from beta cells is glucose independent:</span></strong><span style=\"font-size:12.0pt\"> This is incorrect. Glucose is the primary stimulator of insulin secretion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucose levels below 70 mg/dL shut off insulin secretion to prevent hypoglycemia.</span></span></span></p>",
      "correct_choice_id": 79807,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53841,
      "choices": [
        {
          "id": 214837,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Active neoplasm </span></span></span></p>"
        },
        {
          "id": 214838,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intracranial hypertension </span></span></span></p>"
        },
        {
          "id": 214839,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Uncontrolled diabetes</span></span></span></p>"
        },
        {
          "id": 214840,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertension</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 41-year-old man with a history of cranial radiation is considered for GH therapy. Which of the following is NOT a contraindication? </span></span></p>",
      "unique_key": "Q2843550",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368720,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Hypertension.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While hypertension can be a consideration and requires monitoring during GH therapy, it is not an absolute contraindication. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Contraindications to GH therapy in adults are: active neoplasm, intracranial hypertension, uncontrolled diabetes, retinopathy</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Active neoplasm:</span></strong><span style=\"font-size:12.0pt\"> GH can potentially stimulate the growth of existing tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Intracranial hypertension:</span></strong><span style=\"font-size:12.0pt\"> GH can worsen intracranial pressure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Uncontrolled diabetes:</span></strong><span style=\"font-size:12.0pt\"> GH can impair glucose tolerance and worsen glycemic control.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertension is not an absolute contraindication for GH therapy.</span></span></span></p>",
      "correct_choice_id": 214840,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53835,
      "choices": [
        {
          "id": 214813,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pituitary apoplexy </span></span></span></p>"
        },
        {
          "id": 214814,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sheehan syndrome </span></span></span></p>"
        },
        {
          "id": 214815,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lymphocytic hypophysitis </span></span></span></p>"
        },
        {
          "id": 214816,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prolactinoma</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32-year-old woman presents six weeks postpartum with headaches and visual disturbances. Her ESR is elevated, Prolactin levels are mildly increased, and MRI reveals a pituitary mass. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q7004971",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368716,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Lymphocytic hypophysitis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The likely diagnosis is lymphocytic hypophysitis, which commonly occurs in postpartum women. Most patients have elevated ESR, mildly elevated Prolactin levels and MRI findings usually resemble an adenoma. Usually has a good prognosis if treated early with glucocorticoids.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pituitary apoplexy:</span></strong><span style=\"font-size:12.0pt\"> It is an acute hemorrhagic or ischemic event in the pituitary and presents with sudden onset of severe headache, visual loss, and ophthalmoplegia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Sheehan syndrome:</span></strong><span style=\"font-size:12.0pt\"> This is postpartum hypopituitarism caused by ischemic necrosis of the pituitary gland, usually presenting with lactational failure. Prolactin levels would be low and high ESR in this case cannot be explained by Sheehan&rsquo;s syndrome</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Prolactinoma:</span></strong><span style=\"font-size:12.0pt\"> Close differential but high ESR points towards and inflammatory process than a prolactinoma. To differentiate &ndash; can consider a trial of glucocorticoids</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lymphocytic hypophysitis is a postpartum condition characterized by headaches, visual disturbances, elevated ESR, mildly increased prolactin levels, and MRI findings resembling a pituitary adenoma.</span></span></span></p>",
      "correct_choice_id": 214815,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53845,
      "choices": [
        {
          "id": 214853,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Pituitary adenoma </span></span></span></p>"
        },
        {
          "id": 214854,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Craniopharyngioma </span></span></span></p>"
        },
        {
          "id": 214855,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Germinoma </span></span></span></p>"
        },
        {
          "id": 214856,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pinealoma</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 15-year-old boy presents with headaches, visual field deficits, and growth retardation. CT scan of the head is shown. What is the most likely diagnosis?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-164409.png\" style=\"height:364px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q1423220",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368723,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Craniopharyngioma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The classic triad of symptoms: headaches, visual field deficits, and growth retardation (due to pituitary hormone deficiencies) with imaging typically showing suprasellar mass with calcifications suggests a diagnosis of craniopharyngioma. Craniopharyngiomas are benign tumors that arise from Rathke&#39;s pouch remnants.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pituitary adenoma:</span></strong><span style=\"font-size:12.0pt\"> While pituitary adenomas can cause similar symptoms, they are less likely to present with calcifications and typically arise within the pituitary gland itself, not in the suprasellar region.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Germinoma:</span></strong><span style=\"font-size:12.0pt\"> These tumors are more common in the pineal gland and usually present with Parinaud syndrome (upward gaze palsy, pupillary abnormalities) and obstructive hydrocephalus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pinealoma:</span></strong><span style=\"font-size:12.0pt\"> These tumors arise from the pineal gland and can also present with Parinaud syndrome and obstructive hydrocephalus. They are less likely to have a cystic appearance with calcifications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Important DD for sellar/suprasellar masses:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Craniopharyngioma: </span></strong></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Benign, suprasellar cystic masses derived from Rathke&#39;s pouch.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Presents with a triad of headaches, visual field deficits, and hypopituitarism.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Presents usually &lt; 20 years if age and the most common type is adamantinomatous (large, cystic, lobulated, locally invasive, and partially calcified, usually has CTNNB1 (&beta;-catenin gene mutations)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypopituitarism is seen in ~90% and diabetes insipidus in ~10%. So, most patients require lifelong pituitary hormone replacement.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Treatment: Surgical resection followed by radiation of residual tumor (Surgery alone is curative in only &lt;50% cases due to recurrences. Radiotherapy improves 10-year survival to 70-90% but slightly increases the risk of secondary malignancies).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BRAF inhibitors may be effective in some cases with BRAF V600E mutations (especially in the adult papillary types). </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Rathke&#39;s Cysts:</span></strong></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Occues due to failure of Rathke&#39;s pouch obliteration.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mostly asymptomatic. ~33% present in adulthood with compressive symptoms, diabetes insipidus, and hyperprolactinemia.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pathognomonic large dot sign in MRI</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-164911.png\" style=\"height:610px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Craniopharyngiomas commonly present with headaches, visual field deficits, and growth retardation, and are characterized by suprasellar masses with calcifications on imaging.</span></span></span></p>",
      "correct_choice_id": 214854,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53811,
      "choices": [
        {
          "id": 214717,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">JAK-STAT pathway </span></span></span></p>"
        },
        {
          "id": 214718,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MAPK pathway </span></span></span></p>"
        },
        {
          "id": 214719,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PI3K/Akt pathway </span></span></span></p>"
        },
        {
          "id": 214720,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">cAMP/PKA pathway</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old patient presents with large hands, coarse face and headache. MRI shows a pituitary tumor. Which of the following signaling pathways is most likely activated by the hormone involved in the pathology?</span></span></p>",
      "unique_key": "Q6516191",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368707,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) JAK-STAT pathway</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient is suffering from acromegaly and it is due to Growth hormone (GH) excess. Growth hormone receptors belong to the class of cytokine receptors that primarily signal through the JAK-STAT pathway. This pathway leads to the activation of transcription factors involved in growth and metabolism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. MAPK pathway:</span></strong><span style=\"font-size:12.0pt\"> While GH can activate MAPK pathways, it&#39;s not the primary signaling mechanism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. PI3K/Akt pathway:</span></strong><span style=\"font-size:12.0pt\"> GH also activates the PI3K/Akt pathway, but it&#39;s not the primary pathway.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. cAMP/PKA pathway:</span></strong><span style=\"font-size:12.0pt\"> This pathway is primarily activated by G-protein coupled receptors, not GH receptors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Growth hormone (GH) primarily signals through the JAK-STAT pathway.</span></span></span></p>",
      "correct_choice_id": 214717,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19980,
      "choices": [
        {
          "id": 79881,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal glucose tolerance </span></span></span></p>"
        },
        {
          "id": 79882,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Impaired glucose tolerance </span></span></span></p>"
        },
        {
          "id": 79883,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetes Mellitus </span></span></span></p>"
        },
        {
          "id": 79884,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">None of the above</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old patient came with the following reports. What is the likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-093727.png\" style=\"height:212px; width:500px\" /></span></span></p>",
      "unique_key": "Q3630101",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368695,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Diabetes Mellitus</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s blood glucose values meet the criteria for diabetes mellitus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">FBS (Fasting Blood Sugar):</span></strong><span style=\"font-size:12.0pt\"> 138 mg/dL is above the normal range (&lt;100 mg/dL) and within the range for diabetes (&ge;126 mg/dL).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">2-hour PG (2-hour Postprandial Glucose):</span></strong><span style=\"font-size:12.0pt\"> 260 mg/dL is well above the normal range (&lt;140 mg/dL) and the range for impaired glucose tolerance (140-199 mg/dL), indicating diabetes (&ge;200 mg/dL).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">HbA1c (Glycated Hemoglobin):</span></strong><span style=\"font-size:12.0pt\"> 7.9% is above the normal range (&lt;5.7%) and the range for prediabetes (5.7-6.4%), confirming the diagnosis of diabetes (&ge;6.5%).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Normal glucose tolerance:</span></strong><span style=\"font-size:12.0pt\"> All values should be within the normal range for this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Impaired glucose tolerance:</span></strong><span style=\"font-size:12.0pt\"> The 2-hour PG value is too high for this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. None of the above:</span></strong><span style=\"font-size:12.0pt\"> The correct answer is listed in the options.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetes Mellitus is diagnosed with fasting blood sugar &ge;126 mg/dL, 2-hour postprandial glucose &ge;200 mg/dL, or HbA1c &ge;6.5%.</span></span></span></p>",
      "correct_choice_id": 79883,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19989,
      "choices": [
        {
          "id": 79917,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Preprandial 80-130 mg/dL </span></span></span></p>"
        },
        {
          "id": 79918,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Postprandial &lt; 180 mg/dL </span></span></span></p>"
        },
        {
          "id": 79919,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA1C &lt; 7% </span></span></span></p>"
        },
        {
          "id": 79920,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Goals should be more stringent in older adults</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is incorrect regarding glycemic targets in non-pregnant diabetics?</span></span></p>",
      "unique_key": "Q9411414",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368702,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Goals should be more stringent in older adults</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The American Diabetes Association (ADA) recommends that glycemic targets should be individualized for each patient, taking into account their age, overall health, and risk of hypoglycemia. While a HbA1c goal of &lt;7.0% is appropriate for many non-pregnant adults with diabetes, <strong>less stringent goals</strong> may be appropriate for older adults, especially those with a history of severe hypoglycemia, limited life expectancy, or advanced microvascular or macrovascular complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Preprandial 80-130 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> This is the correct target range for preprandial capillary plasma glucose according to the ADA guidelines.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Postprandial &lt; 180 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> This is the correct target range for peak postprandial capillary plasma glucose according to the ADA guidelines.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. HbA1C &lt; 7%:</span></strong><span style=\"font-size:12.0pt\"> This is the general target for HbA1c in most non-pregnant adults with diabetes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Summary:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-095420.png\" style=\"height:507px; width:1000px\" /></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glycemic targets in older adults should be less stringent due to increased risk of hypoglycemia.</span></span></span></p>",
      "correct_choice_id": 79920,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53837,
      "choices": [
        {
          "id": 214821,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">III cranial nerve (CN) palsy </span></span></span></p>"
        },
        {
          "id": 214822,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertension </span></span></span></p>"
        },
        {
          "id": 214823,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypoglycaemia </span></span></span></p>"
        },
        {
          "id": 214824,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Visual field defects</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with a known pituitary adenoma presents to the emergency department with sudden onset of severe headache, visual disturbances, and vomiting. Which of the following is NOT an expected complication?</span></span></p>",
      "unique_key": "Q8957283",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368718,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Hypertension</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This is a case of pituitary apoplexy. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Causes:</span></strong><span style=\"font-size:12.0pt\"> Hemorrhage into a pre-existing adenoma (most common), Sheehan&#39;s syndrome</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Risk Factors:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Pituitary adenoma, Diabetes, Hypertension, Sickle cell disease, PPH/shock</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Symptoms &amp; Complications:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Severe headache with meningeal irritation , visual field defects, Ophthalmoplegia (Most commonly III &gt; VI CN palsy</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Can cause Cardiovascular collapse and/or Loss of consciousness (in severe cases).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Severe hypoglycemia, Hypotension and shock, Death</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Diagnosis:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Pituitary CT or MRI (usually shows sellar mass with hemorrhage)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Management:</span></strong><span style=\"font-size:12.0pt\"> High dose glucocorticoids. Urgent surgery if LOC/ophthalmoplegia</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. III CN palsy:</span></strong><span style=\"font-size:12.0pt\"> Most common cranial nerve injured in apoplexy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hypoglycemia:</span></strong><span style=\"font-size:12.0pt\"> Hypopituitarism can result in secondary adrenal insufficiency, leading to low cortisol levels and hypoglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Visual field defects:</span></strong><span style=\"font-size:12.0pt\"> Compression of the optic chiasm by the pituitary mass can cause bitemporal hemianopsia or other visual field defects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertension is not an expected complication of pituitary apoplexy.</span></span></span></p>",
      "correct_choice_id": 214822,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53810,
      "choices": [
        {
          "id": 214713,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">JAK-STAT pathway </span></span></span></p>"
        },
        {
          "id": 214714,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MAPK pathway </span></span></span></p>"
        },
        {
          "id": 214715,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PI3K/Akt pathway </span></span></span></p>"
        },
        {
          "id": 214716,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smad pathway</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman presents with progressive muscle weakness and a distinctive heliotrope rash around her eyes. A muscle biopsy reveals endomysial inflammation and fibrosis. Which of the following signaling pathways is most likely implicated in the pathogenesis of her condition? </span></span></p>",
      "unique_key": "Q9363324",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368706,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Smad pathway </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation is consistent with dermatomyositis, an autoimmune inflammatory myopathy. Transforming growth factor beta (TGF-&beta;) plays a crucial role in the pathogenesis of dermatomyositis, and its signaling occurs through the Smad pathway, leading to fibrosis and muscle damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. JAK-STAT pathway:</span></strong><span style=\"font-size:12.0pt\"> This pathway is primarily involved in cytokine signaling and immune responses.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. MAPK pathway:</span></strong><span style=\"font-size:12.0pt\"> This pathway is involved in various cellular processes, including proliferation and differentiation, but is not the primary pathway implicated in dermatomyositis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. PI3K/Akt pathway:</span></strong><span style=\"font-size:12.0pt\"> This pathway is involved in cell survival and growth, but not the primary pathway implicated in dermatomyositis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Receptor Tyrosine Kinase -&nbsp; Insulin, IGF-I EGF, NGF</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cytokine Receptor Linked Kinase - GH, PRL</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serine Kinase - Activin, TGF-&beta;, MIS</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-150602.png\" style=\"height:342px; width:500px\" /></span></span></span></p>",
      "correct_choice_id": 214716,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20098,
      "choices": [
        {
          "id": 80353,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Empagliflozin </span></span></span></p>"
        },
        {
          "id": 80354,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dulaglutide </span></span></span></p>"
        },
        {
          "id": 80355,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pioglitazone </span></span></span></p>"
        },
        {
          "id": 80356,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sitagliptin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 54-year-old diabetic patient presents with breathlessness to the emergency department. On evaluation, the patient&#39;s ejection fraction (EF) is 35%. Which of the following medications should be avoided for the treatment of diabetes in this patient?</span></span></p>",
      "unique_key": "Q9605039",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368691,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Pioglitazone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pioglitazone, a thiazolidinedione (TZD), is contraindicated in patients with symptomatic heart failure due to its potential to worsen fluid retention and exacerbate heart failure. A reduced ejection fraction (EF) of 35% indicates systolic heart failure, making pioglitazone an inappropriate choice for this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Empagliflozin (SGLT2 inhibitor):</span></strong><span style=\"font-size:12.0pt\"> Empagliflozin has been shown to have cardioprotective effects and can be beneficial in patients with heart failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Dulaglutide (GLP-1 receptor agonist):</span></strong><span style=\"font-size:12.0pt\"> GLP-1 receptor agonists like dulaglutide have shown cardiovascular benefits and may be considered in patients with heart failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sitagliptin (DPP-4 inhibitor):</span></strong><span style=\"font-size:12.0pt\"> DPP-4 inhibitors are generally safe in patients with heart failure and do not have significant negative effects on cardiac function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Avoid pioglitazone in patients with symptomatic heart failure due to the risk of fluid retention and exacerbation of heart failure.</span></span></span></p>",
      "correct_choice_id": 80355,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53855,
      "choices": [
        {
          "id": 214893,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Central diabetes insipidus (DI) </span></span></span></p>"
        },
        {
          "id": 214894,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nephrogenic DI </span></span></span></p>"
        },
        {
          "id": 214895,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary polydipsia </span></span></span></p>"
        },
        {
          "id": 214896,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old male presents with complaints of excessive thirst (polydipsia) and frequent urination (polyuria), both during the day and at night. A 24-hour urine collection reveals a volume of 5 liters with an osmolality of 250 mOsm/L. Basal plasma ADH is 0.5pg/mL. MRI of the pituitary is shown. Which of the following is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-170840.png\" style=\"height:299px; width:300px\" /></span></span></p>",
      "unique_key": "Q7635996",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368731,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Primary polydipsia (DI)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s high urine output (&gt;40 mL/kg/24 hours), low urine osmolality (&lt;300 mOsm/L), low ADH levels (&lt; 1 pg/mL) and intact posterior pituitary bright spot are all consistent with primary polydipsia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Central DI:</span></strong><span style=\"font-size:12.0pt\"> MRI would have revealed an absent posterior pituitary bright spot. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Nephrogenic DI:</span></strong><span style=\"font-size:12.0pt\"> This is caused by resistance to ADH in the kidneys, and would typically present with ADH level of &gt; 1pg/mL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion):</span></strong><span style=\"font-size:12.0pt\"> This would not cause polyuria and polydipsia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary polydipsia is characterized by high urine output, low urine osmolality, low ADH levels, and an intact posterior pituitary bright spot on MRI.</span></span></span></p>",
      "correct_choice_id": 214895,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53901,
      "choices": [
        {
          "id": 215077,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Leptin </span></span></span></p>"
        },
        {
          "id": 215078,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adiponectin </span></span></span></p>"
        },
        {
          "id": 215079,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin</span></span></span></p>"
        },
        {
          "id": 215080,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TNF-&alpha;</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is reduced in obese patients?</span></span></span></p>",
      "unique_key": "Q3879598",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368696,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Adiponectin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adiponectin is a hormone produced by adipocytes (fat cells) that plays a role in regulating glucose and lipid metabolism. It has anti-inflammatory and insulin-sensitizing effects. In obese patients, adiponectin levels are often <strong>reduced</strong>, contributing to insulin resistance and the development of metabolic syndrome. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Leptin:</span></strong><span style=\"font-size:12.0pt\"> Leptin levels are typically elevated in obese patients, but its signaling is often impaired (leptin resistance). Elevated leptin is associated with endothelial damage resulting in CV risk. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Insulin:</span></strong><span style=\"font-size:12.0pt\"> Insulin levels are often elevated in obese patients due to insulin resistance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. TNF-&alpha;:</span></strong><span style=\"font-size:12.0pt\"> TNF-&alpha; (and IL-6) is increased in obesity, contributing to the chronic low-grade inflammation, which can cause endothelial injury and increase CV risk. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adiponectin levels are reduced in obese patients, contributing to insulin resistance and metabolic syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Adipokines in Obesity:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><u><span style=\"font-size:12.0pt\">Increased:</span></u><span style=\"font-size:12.0pt\"> Leptin, Insulin, Resistin, Proinflammatory cytokines (IL6/ TNF &alpha;)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><u><span style=\"font-size:12.0pt\">Decreased<em>:</em></span></u><span style=\"font-size:12.0pt\"> Adiponectin, Ghrelin</span></span></span></li>\r\n</ul>",
      "correct_choice_id": 215078,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53816,
      "choices": [
        {
          "id": 214737,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lactotrophs </span></span></span></p>"
        },
        {
          "id": 214738,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gonadotrophs </span></span></span></p>"
        },
        {
          "id": 214739,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thyrotrophs </span></span></span></p>"
        },
        {
          "id": 214740,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corticotrophs</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following pituitary cell type would appear earliest in the fetus?</span></span></span></p>",
      "unique_key": "Q5782914",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368711,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Corticotrophs</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corticotrophs, the cells responsible for producing adrenocorticotropic hormone (ACTH), are the earliest to appear in the fetal pituitary gland, at around 6 weeks of gestation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Lactotrophs:</span></strong><span style=\"font-size:12.0pt\"> These cells produce prolactin and appear around 12 weeks of gestation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Gonadotrophs:</span></strong><span style=\"font-size:12.0pt\"> These cells produce FSH and LH and also appear around 12 weeks of gestation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Thyrotrophs:</span></strong><span style=\"font-size:12.0pt\"> These cells produce TSH and also appear around 12 weeks of gestation. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-154029.png\" style=\"height:758px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corticotrophs are the earliest pituitary cells to appear in the fetus, around 6 weeks of gestation.</span></span></span></p>",
      "correct_choice_id": 214740,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20089,
      "choices": [
        {
          "id": 80317,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metformin </span></span></span></p>"
        },
        {
          "id": 80318,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Canagliflozin </span></span></span></p>"
        },
        {
          "id": 80319,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Semaglutide </span></span></span></p>"
        },
        {
          "id": 80320,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pioglitazone</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with type 2 diabetes on insulin was recently started on a new drug. After a week, she presents with nausea, vomiting, abdominal pain, near-normal blood glucose, elevated anion gap metabolic acidosis, and elevated plasma ketones. Which of the following medications is the most likely cause?</span></span></p>",
      "unique_key": "Q7706261",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368737,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Canagliflozin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation is consistent with euglycemic diabetic ketoacidosis (euDKA), a rare but serious complication of diabetes. While DKA is typically associated with high blood glucose levels, euDKA occurs with near-normal or even low blood glucose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Canagliflozin, an SGLT2 inhibitor, is known to increase the risk of euDKA. It works by increasing urinary glucose excretion, which can lead to a relative deficit of glucose available for energy. This can trigger the body to break down fat for fuel, producing ketones and leading to acidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Metformin:</span></strong><span style=\"font-size:12.0pt\"> Metformin can rarely cause lactic acidosis but not associated with euDKA. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Semaglutide:</span></strong><span style=\"font-size:12.0pt\"> Semaglutide (a GLP-1 receptor agonist) is not associated with euDKA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pioglitazone:</span></strong><span style=\"font-size:12.0pt\"> Pioglitazone (a thiazolidinedione) is not known to cause euDKA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Canagliflozin, an SGLT2 inhibitor, can cause euglycemic diabetic ketoacidosis (euDKA).</span></span></span></p>",
      "correct_choice_id": 80318,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19988,
      "choices": [
        {
          "id": 79913,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CV (Coefficient of Variation) is an equivalent of HbA1c </span></span></span></p>"
        },
        {
          "id": 79914,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CGM measures interstitial glucose </span></span></span></p>"
        },
        {
          "id": 79915,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low rates of hypo and hyperglycemia if used with insulin infusion device </span></span></span></p>"
        },
        {
          "id": 79916,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CGM can detect hypoglycemic unawareness</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is false regarding Continuous Glucose Monitoring (CGM) in diabetes?</span></span></p>",
      "unique_key": "Q8316543",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368701,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) CV (Coefficient of Variation) is an equivalent of HbA1c</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">CV and HbA1c are not equivalent:</span></strong><span style=\"font-size:12.0pt\"> The coefficient of variation (CV) measures glucose variability, or how much glucose levels fluctuate. GMI (Glucose Management Indicator) is a vague equivalent of HbA1C since both indicate MBG (Mean Blood Glucose).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CGM measures interstitial glucose:</span></strong><span style=\"font-size:12.0pt\"> CGM does not directly measure blood glucose. It measures glucose levels in the interstitial fluid, which closely reflects blood glucose but with a slight time lag.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Low rates of hypo and hyperglycemia if used with insulin infusion device:</span></strong><span style=\"font-size:12.0pt\"> CGM, especially when integrated with insulin pumps (forming a hybrid closed-loop system), can significantly reduce the risk of hypoglycemia and hyperglycemia by providing real-time data and automated insulin adjustments.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CGM can detect hypoglycemic unawareness:</span></strong><span style=\"font-size:12.0pt\"> CGM can alert patients to impending hypoglycemia, even if they are not experiencing typical symptoms, thus helping to prevent severe hypoglycemic events.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coefficient of Variation (CV) measures glucose variability and is not equivalent to HbA1c.</span></span></span></p>",
      "correct_choice_id": 79913,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19963,
      "choices": [
        {
          "id": 79813,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antibodies </span></span></span></p>"
        },
        {
          "id": 79814,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CD4 T cells </span></span></span></p>"
        },
        {
          "id": 79815,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CD8 T cells </span></span></span></p>"
        },
        {
          "id": 79816,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inflammatory cytokines</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In type 1 diabetes, &beta; cell destruction is primarily mediated by:</span></span></span></p>",
      "unique_key": "Q6711529",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368725,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) CD8 T cells</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While all of the listed options play a role in the pathogenesis of type 1 diabetes, the direct destruction of beta cells is primarily mediated by cytotoxic CD8+ T cells. These cells recognize specific antigens presented on the surface of beta cells and induce apoptosis, leading to their destruction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Antibodies:</span></strong><span style=\"font-size:12.0pt\"> Autoantibodies against beta cell antigens are present in type 1 diabetes and serve as markers of the disease, but they do not directly cause beta cell death.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CD4 T cells:</span></strong><span style=\"font-size:12.0pt\"> CD4 T cells play a role in activating and coordinating the immune response, but they are not the primary mediators of beta cell destruction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Inflammatory cytokines:</span></strong><span style=\"font-size:12.0pt\"> Cytokines released by immune cells contribute to the inflammatory environment and can indirectly damage beta cells, but the direct killing is primarily mediated by CD8+ T cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><u>Educational Objective</u>: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CD8 T cells are the primary mediators of &beta; cell destruction in type 1 diabetes.</span></span></span></p>",
      "correct_choice_id": 79815,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53829,
      "choices": [
        {
          "id": 214789,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypothyroidism</span></span></span></p>"
        },
        {
          "id": 214790,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypogonadism</span></span></span></p>"
        },
        {
          "id": 214791,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperprolactinemia</span></span></span></p>"
        },
        {
          "id": 214792,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH deficiency</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the most common feature of adult hypopituitarism?</span></span></p>",
      "unique_key": "Q8698550",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368715,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Hypogonadism</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypogonadism is the most common presenting feature of adult hypopituitarism even when other pituitary hormones are also deficient. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hypothyroidism:</span></strong><span style=\"font-size:12.0pt\"> Common, but not as frequent as hypogonadism in adults</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hyperprolactinemia:</span></strong><span style=\"font-size:12.0pt\"> Less common and usually associated with prolactinomas. Note that even hyperprolactinemia&rsquo;s are associated with hypogonadism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. GH deficiency:</span></strong><span style=\"font-size:12.0pt\"> Common, but not as frequent as hypogonadism in adults</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypogonadism is the most common presenting feature of adult hypopituitarism.</span></span></span></p>",
      "correct_choice_id": 214790,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53852,
      "choices": [
        {
          "id": 214881,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Most common cause is GH cell adenoma</span></span></span></p>"
        },
        {
          "id": 214882,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">25% co-secrete prolactin</span></span></span></p>"
        },
        {
          "id": 214883,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Malignancies are the commonest cause of death</span></span></span></p>"
        },
        {
          "id": 214884,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Survival is 10 years lesser in acromegalics</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old man presents with features suggestive of acromegaly. Which of the following is incorrect?</span></span></p>",
      "unique_key": "Q7725314",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368729,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Malignancies are the commonest cause of death</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While acromegaly can be associated with an increased risk of certain malignancies, the most common cause of death in patients with acromegaly is cardiovascular disease. This is due to the multiple effects of excess growth hormone on the cardiovascular system, including hypertension, left ventricular hypertrophy, and increased risk of arrhythmias and heart failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Most common cause is GH cell adenoma:</span></strong><span style=\"font-size:12.0pt\"> Common causes of acromegaly are densely or sparsely granulated GH cell adenoma (60%) &gt; Mixed GH cell and PRL cell adenoma (25%), Mammosomatotrope cell adenoma (10%)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 25% co-secrete prolactin:</span></strong><span style=\"font-size:12.0pt\"> A significant proportion of GH-secreting tumors also co-secrete prolactin, leading to symptoms such as galactorrhea and menstrual irregularities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Survival is 10 years lesser in acromegalics:</span></strong><span style=\"font-size:12.0pt\"> Untreated acromegaly can significantly reduce life expectancy, primarily due to cardiovascular complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most common cause of death in patients with acromegaly is cardiovascular disease, not malignancies.</span></span></span></p>",
      "correct_choice_id": 214883,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53847,
      "choices": [
        {
          "id": 214861,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MEN1 </span></span></span></p>"
        },
        {
          "id": 214862,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Carney complex</span></span></span></p>"
        },
        {
          "id": 214863,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MEN4 </span></span></span></p>"
        },
        {
          "id": 214864,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pallister hall syndrome</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All of the following are familial pituitary tumour syndromes except? </span></span></span></p>",
      "unique_key": "Q2087152",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368726,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Pallister-Hall syndrome.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pallister-Hall syndrome (due to mutations in GLI3 gene) is a rare genetic disorder characterized by various developmental abnormalities, including hypothalamic hamartoma, imperforate anus, and polydactyly. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While hypothalamic hamartomas can cause endocrine dysfunction, Pallister-Hall syndrome is not primarily considered a familial pituitary tumor syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. MEN1 (Multiple Endocrine Neoplasia type 1):</span></strong><span style=\"font-size:12.0pt\"> This syndrome is characterized by tumors of the parathyroid glands, pituitary gland, and pancreas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Carney complex:</span></strong><span style=\"font-size:12.0pt\"> This syndrome is associated with various tumors, including pituitary adenomas, cardiac myxomas, and pigmented skin lesions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. MEN4 (Multiple Endocrine Neoplasia type 4):</span></strong><span style=\"font-size:12.0pt\"> This rare syndrome is similar to MEN1 but is caused by mutations in a different gene (CDKN1B).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pallister-Hall syndrome, characterized by hypothalamic hamartoma, imperforate anus, and polydactyly, is not primarily a familial pituitary tumor syndrome.</span></span></span></p>",
      "correct_choice_id": 214864,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20094,
      "choices": [
        {
          "id": 80337,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metformin </span></span></span></p>"
        },
        {
          "id": 80338,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Linagliptin </span></span></span></p>"
        },
        {
          "id": 80339,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Empagliflozin </span></span></span></p>"
        },
        {
          "id": 80340,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin Glargine</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 43-year-old lady presents with a 3-month history of 7 kg weight loss despite increased appetite and nocturia. Lab reports showed a fasting blood sugar (FBS) of 331 mg/dL and an HbA1c of 11.2%. Which of the following would be the most appropriate initial therapy?</span></span></p>",
      "unique_key": "Q8379737",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368739,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Insulin Glargine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient presents with significant hyperglycemia (elevated FBS and HbA1c) along with classic symptoms of diabetes (weight loss, polyuria, polydipsia). This presentation, combined with the rapid weight loss, suggests a new-onset type 1 or ketosis-prone type 2 diabetes mellitus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Insulin&nbsp;</span></strong><span style=\"font-size:12.0pt\">is recommended as the first injectable in patients who are having severe hyperglycemia (FBS &gt; 300 or A1C &gt; 10%) and/or those who are symptomatic (like in this case).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Metformin:</span></strong><span style=\"font-size:12.0pt\"> While metformin is a first-line agent for type 2 diabetes, it is not appropriate for initial therapy in patients with severe hyperglycemia or those suspected of having type 1 diabetes due to the risk of lactic acidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Linagliptin:</span></strong><span style=\"font-size:12.0pt\"> This is a DPP-4 inhibitor that increases incretin levels, promoting insulin release and decreasing glucagon secretion. It is not potent enough to manage the severe hyperglycemia in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Empagliflozin:</span></strong><span style=\"font-size:12.0pt\"> This is an SGLT2 inhibitor that increases urinary glucose excretion. While it can help lower blood sugar, it can also increase the risk of euglycemic DKA, especially in patients with significant hyperglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin is recommended for patients with severe hyperglycemia (FBS &gt; 300 or A1C &gt; 10%) and/or those who are symptomatic.</span></span></span></p>",
      "correct_choice_id": 80340,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20101,
      "choices": [
        {
          "id": 80365,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proliferative retinopathy </span></span></span></p>"
        },
        {
          "id": 80366,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ESRD (End-Stage Renal Disease) </span></span></span></p>"
        },
        {
          "id": 80367,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neuropathy </span></span></span></p>"
        },
        {
          "id": 80368,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripheral arterial disease</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is a contraindication for vigorous exercise in individuals with diabetes?</span></span></p>",
      "unique_key": "Q7453131",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368692,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Proliferative retinopathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proliferative retinopathy is a severe form of diabetic eye disease characterized by the growth of new blood vessels in the retina. These vessels are fragile and prone to bleeding, which can lead to vision loss. Vigorous exercise can increase the risk of bleeding in the eye and potentially worsen retinopathy. Therefore, it is a contraindication for strenuous physical activity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. ESRD (End-Stage Renal Disease):</span></strong><span style=\"font-size:12.0pt\"> While exercise should be adjusted based on kidney function and individual tolerance, it is not an absolute contraindication.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Neuropathy:</span></strong><span style=\"font-size:12.0pt\"> Exercise is generally encouraged in patients with diabetic neuropathy, as it can help improve nerve function and reduce pain. However, certain types of exercise may need to be modified based on the severity of neuropathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Peripheral arterial disease (PAD):</span></strong><span style=\"font-size:12.0pt\"> Exercise can actually be beneficial for PAD as it improves circulation and reduces symptoms. However, the intensity and duration should be adjusted based on the severity of PAD and the individual&#39;s tolerance. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vigorous exercise is contraindicated in individuals with proliferative retinopathy due to the risk of retinal bleeding.</span></span></span></p>",
      "correct_choice_id": 80365,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53898,
      "choices": [
        {
          "id": 215065,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HDL cholesterol level of 58 mg/dL </span></span></span></p>"
        },
        {
          "id": 215066,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Triglyceride level of 160 mg/dL</span></span></span></p>"
        },
        {
          "id": 215067,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Taking a statin for hypercholesterolemia </span></span></span></p>"
        },
        {
          "id": 215068,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BMI of 28 kg/m&sup2;</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman from Chennai presents with a waist circumference of 92 cm, a blood pressure of 120/80 mmHg, and a fasting blood glucose of 110 mg/dL. Which of the following additional findings would be needed to diagnose metabolic syndrome?</span></span></p>",
      "unique_key": "Q6748120",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368693,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Triglyceride level of 160 mg/dL</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">According to the harmonizing definition of metabolic syndrome, at least 3 of the following five criteria are needed for diagnosis:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Abdominal obesity:</span></strong><span style=\"font-size:12.0pt\"> Waist circumference &gt;90cm for South Asian women (which the patient meets with 92 cm)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Triglycerides:</span></strong><span style=\"font-size:12.0pt\"> &ge;150 mg/dL (1.7 mmol/L) (which the patient would meet with 160 mg/dL)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">HDL cholesterol:</span></strong><span style=\"font-size:12.0pt\"> &lt;50 mg/dL (1.29 mmol/L) in women</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Blood pressure:</span></strong><span style=\"font-size:12.0pt\"> &ge;130/85 mmHg or on antihypertensive medication</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Fasting glucose:</span></strong><span style=\"font-size:12.0pt\"> &ge;100 mg/dL (5.6 mmol/L) or diagnosed type 2 diabetes (which the patient meets with 110 mg/dL)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient already meets the criteria for abdominal obesity and impaired fasting glucose. With the additional finding of elevated triglycerides (&ge;150 mg/dL), she would meet three criteria and thus be diagnosed with metabolic syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-100019.png\" style=\"height:653px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. HDL cholesterol level of 58 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> This is within normal limits (&gt;50 mg/dL) and does not contribute to the diagnosis of metabolic syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Taking a statin for hypercholesterolemia:</span></strong><span style=\"font-size:12.0pt\"> This is a treatment for high cholesterol but is not a diagnostic criterion for metabolic syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. BMI of 28 kg/m&sup2;:</span></strong><span style=\"font-size:12.0pt\"> This is considered overweight but not obese, and while it can be associated with metabolic syndrome, it is not a direct diagnostic criterion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metabolic syndrome diagnosis requires at least three criteria, including central obesity, elevated triglycerides, low HDL cholesterol, high blood pressure, or high fasting glucose.</span></span></span></p>",
      "correct_choice_id": 215066,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20091,
      "choices": [
        {
          "id": 80325,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Liraglutide </span></span></span></p>"
        },
        {
          "id": 80326,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Dulaglutide </span></span></span></p>"
        },
        {
          "id": 80327,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Semaglutide </span></span></span></p>"
        },
        {
          "id": 80328,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tirzepatide</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old woman with type 2 diabetes mellitus and obesity presents to the clinic. She is currently taking metformin 1000 mg twice daily, but her glycemic control remains suboptimal (HbA1c 8.5%). She is interested in a medication that can help with both weight loss and glucose control. Which of the following medications would be most appropriate for this patient?</span></span></p>",
      "unique_key": "Q1225117",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368738,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Tirzepatide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, making it a suitable option for patients with type 2 diabetes who need both improved glycemic control and weight loss. It has been shown to be more effective than other GLP-1 receptor agonists in achieving these goals.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Liraglutide, Option B. Dulaglutide&nbsp;</span></strong><span style=\"font-size:12.0pt\">and </span><strong><span style=\"font-size:12.0pt\">Option C. Semaglutide:</span></strong><span style=\"font-size:12.0pt\"> While these GLP-1 receptor agonists can promote weight loss and improve glycemic control, tirzepatide has shown superior efficacy in clinical trials compared to these options.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tirzepatide, a dual GIP and GLP-1 receptor agonist, is highly effective for both glycemic control and weight loss in type 2 diabetes.</span></span></span></p>",
      "correct_choice_id": 80328,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53838,
      "choices": [
        {
          "id": 214825,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metyrapone test </span></span></span></p>"
        },
        {
          "id": 214826,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">l-Arginine test </span></span></span></p>"
        },
        {
          "id": 214827,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CRH test </span></span></span></p>"
        },
        {
          "id": 214828,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACTH stimulation test</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following tests are used for ACTH deficiency, except?</span></span></p>",
      "unique_key": "Q4778001",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368719,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) l-Arginine test</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The l-Arginine test is used to assess growth hormone (GH) reserve, not ACTH deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Metyrapone test:</span></strong><span style=\"font-size:12.0pt\"> Tests the integrity of the hypothalamic-pituitary-adrenal (HPA) axis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CRH test:</span></strong><span style=\"font-size:12.0pt\"> Directly stimulates the pituitary to release ACTH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. ACTH stimulation test:</span></strong><span style=\"font-size:12.0pt\"> Assesses the adrenal glands&#39; ability to respond to ACTH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Summary:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tests for ACTH deficiency: </span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACTH test (Standard &amp; low dose &ndash; test cortisol, level &gt; 21 &mu;g/dL is normal)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin tolerance test (test cortisol, level &gt; 20 &mu;g/dL is normal)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CRH test (test ACTH and cortisol, cortisol level &gt; 20 &mu;g/dL is normal). </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metyrapone test (test 11 deoxy cortisol and ACTH) &ndash; outdated, not in use.</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tests for GH deficiency: Insulin tolerance test, GHRH test, l-Arginine test, l-Dopa test, ghrelin test (macimoerlin test - ORAL) &amp; glucagon test. Facts on Adult GH deficiency -</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin tolerance test is the 1<sup>st</sup> line test but C/I in diabetes, ischemic heart disease, cerebrovascular disease, epilepsy and elderly. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH &gt;3 &mu;g/L in response to hypoglycemia (&lt; 40mg/dL) is considered as the normal response (GH &lt; 3 &mu;g/L is suggestive of GH deficiency). </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adult GH deficiency is associated with changes in body composition (reduced lean body mass, increased fat mass with selective deposition of intraabdominal visceral fat, and increased waist-to-hip ratio), Hyperlipidemia, LV dysfunction, hypertension, and reduced bone mineral density.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adult hypopituitarism is associated with a 3x increase in CV mortality</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The l-Arginine test is used to assess growth hormone (GH) reserve, not ACTH deficiency.</span></span></span></p>",
      "correct_choice_id": 214826,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53812,
      "choices": [
        {
          "id": 214721,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Familial hypocalciuric hypercalcemia (FHH) </span></span></span></p>"
        },
        {
          "id": 214722,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Familial hypocalciuric hypocalcemia </span></span></span></p>"
        },
        {
          "id": 214723,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neonatal severe hyperparathyroidism (NSHPT) </span></span></span></p>"
        },
        {
          "id": 214724,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Familial hypocalcemic hypercalciuria</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Genetic testing of a patient reveals a homozygous inactivating mutation in the calcium-sensing receptor (CaSR) gene. Which of the following is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q7301258",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368708,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Neonatal severe hyperparathyroidism (NSHPT)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">NSHPT</span></strong><span style=\"font-size:12.0pt\"> is a rare autosomal recessive disorder caused by homozygous or compound heterozygous inactivating mutations in the CaSR gene. This leads to severe hypercalcemia due to unsuppressed PTH secretion, often resulting in life-threatening complications in newborns.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Familial hypocalciuric hypercalcemia (FHH):</span></strong><span style=\"font-size:12.0pt\"> FHH is a milder autosomal dominant condition caused by heterozygous CaSR mutations, characterized by mild hypercalcemia and low urinary calcium excretion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Familial hypocalciuric hypocalcemia:</span></strong><span style=\"font-size:12.0pt\"> This is not a recognized condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Familial hypocalcemic hypercalciuria:</span></strong><span style=\"font-size:12.0pt\"> This is caused by activating CaSR mutations, leading to hypocalcemia and high urinary calcium excretion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><u><span style=\"font-size:12.0pt\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Calcium sensing receptor defects &ndash;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Familial hypocalciuric hypercalcemia - AD, inactivating</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neonatal severe hyperparathyroidism- AR, inactivating</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Familial hypocalcemic hypercalciura- AD, activating</span></span></span></p>",
      "correct_choice_id": 214723,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19955,
      "choices": [
        {
          "id": 79781,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ketogenic diet </span></span></span></p>"
        },
        {
          "id": 79782,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prednisolone </span></span></span></p>"
        },
        {
          "id": 79783,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Valproate d</span></span></span></p>"
        },
        {
          "id": 79784,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lamotrigine</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A neonate presents with seizures, microcephaly, and developmental delay. Brain imaging reveals abnormalities in the white matter. Genetic testing confirms a mutation in the SLC2A1 gene. What is the treatment of choice?</span></span></p>",
      "unique_key": "Q5683558",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368736,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Ketogenic diet</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The mutation in the SLC2A1 gene indicates GLUT1 deficiency syndrome, a rare metabolic disorder characterized by impaired glucose transport across the blood-brain barrier. This leads to neuroglycopenia (low glucose in the brain), causing seizures, developmental delay, and movement disorders.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The ketogenic diet is the treatment of choice for GLUT1 deficiency syndrome, bypassing the need for glucose transport via GLUT1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Prednisolone:</span></strong><span style=\"font-size:12.0pt\"> This is a corticosteroid used to treat inflammation and autoimmune conditions. It is not effective in GLUT1 deficiency syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Valproate&nbsp;</span></strong><span style=\"font-size:12.0pt\">and </span><strong><span style=\"font-size:12.0pt\">Option D. Lamotrigine:</span></strong><span style=\"font-size:12.0pt\"> These are anti-seizure medications that are generally ineffective in controlling seizures associated with GLUT1 deficiency syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-091146.png\" style=\"height:416px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GLUT1 deficiency syndrome, caused by SLC2A1 gene mutation, is best treated with a ketogenic diet to bypass glucose transport issues.</span></span></span></p>",
      "correct_choice_id": 79781,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20079,
      "choices": [
        {
          "id": 80277,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspart </span></span></span></p>"
        },
        {
          "id": 80278,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glargine </span></span></span></p>"
        },
        {
          "id": 80279,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NPH </span></span></span></p>"
        },
        {
          "id": 80280,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Regular</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following preparations of insulin has the longest time to onset and the longest duration of action?</span></span></p>",
      "unique_key": "Q8721513",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368734,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Glargine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glargine is a long-acting insulin analog designed to provide a basal level of insulin over an extended period. It has a slow onset of action (1-2 hours) and a prolonged duration of action (20-24 hours), making it suitable for providing consistent background insulin levels throughout the day.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Aspart:</span></strong><span style=\"font-size:12.0pt\"> This is a rapid-acting insulin analog with a quick onset (15-30 minutes) and short duration (3-5 hours).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. NPH:</span></strong><span style=\"font-size:12.0pt\"> This is an intermediate-acting insulin with a slower onset (1-2 hours) and moderate duration (12-18 hours).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Regular:</span></strong><span style=\"font-size:12.0pt\"> This is a short-acting insulin with a relatively quick onset (30-60 minutes) and shorter duration (5-8 hours).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-123019.png\" style=\"height:265px; width:500px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-123213.png\" style=\"height:558px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glargine is a long-acting insulin analog with a slow onset (1-2 hours) and prolonged duration (20-24 hours).</span></span></span></p>",
      "correct_choice_id": 80278,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53848,
      "choices": [
        {
          "id": 214865,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Verapamil</span></span></span></p>"
        },
        {
          "id": 214866,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Methyldopa</span></span></span></p>"
        },
        {
          "id": 214867,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Risperidone</span></span></span></p>"
        },
        {
          "id": 214868,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metoclopramide</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following medications is most likely to cause a significant elevation in prolactin levels, often exceeding 200 &mu;g/L?</span></span></p>",
      "unique_key": "Q3057957",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368727,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Risperidone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PRL secreting pituitary adenomas (prolactinomas) are the most common cause of PRL levels &gt;200 &mu;g/L.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Other causes (drugs/ infiltrative disorders) that elevate PRL levels, usually have PRL in the range of 30&ndash;100 &mu;g/L. Risperidone, is an exception though since it can elevate PRL to levels exceeding 200 &mu;g/L.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Verapamil:</span></strong><span style=\"font-size:12.0pt\"> While verapamil is a calcium channel blocker and can mildly elevate prolactin levels, it typically doesn&#39;t cause levels exceeding 200 &mu;g/L.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Methyldopa:</span></strong><span style=\"font-size:12.0pt\"> Methyldopa is an antihypertensive that can also slightly increase prolactin, but not to the extent seen with risperidone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Metoclopramide:</span></strong><span style=\"font-size:12.0pt\"> Metoclopramide is a dopamine antagonist used for nausea and gastroparesis, and it can elevate prolactin, but typically not to levels above 200 &mu;g/L.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Risperidone can significantly elevate prolactin levels, often exceeding 200 &mu;g/L.</span></span></span></p>",
      "correct_choice_id": 214867,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53906,
      "choices": [
        {
          "id": 215093,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Semaglutide </span></span></span></p>"
        },
        {
          "id": 215094,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Setmelanotide </span></span></span></p>"
        },
        {
          "id": 215095,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Orlistat </span></span></span></p>"
        },
        {
          "id": 215096,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Phentermine</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs is not approved for general obesity?</span></span></p>",
      "unique_key": "Q7851437",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368700,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Setmelanotide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Setmelanotide is not approved for general obesity. It is specifically approved for the treatment of obesity in patients with certain rare genetic conditions, such as proopiomelanocortin (POMC) deficiency, leptin receptor (LEPR) deficiency, or Bardet-Biedl syndrome (BBS).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Semaglutide:</span></strong><span style=\"font-size:12.0pt\"> This GLP-1 receptor agonist is approved for chronic weight management in adults with general obesity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Orlistat:</span></strong><span style=\"font-size:12.0pt\"> This lipase inhibitor is approved for weight loss in adults and adolescents with obesity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Phentermine:</span></strong><span style=\"font-size:12.0pt\"> This appetite suppressant is approved for short-term use in adults with obesity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Setmelanotide is not approved for general obesity but for specific genetic conditions like POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome.</span></span></span></p>",
      "correct_choice_id": 215094,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53904,
      "choices": [
        {
          "id": 215085,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Most common mechanism of imprinting center mutations </span></span></span></p>"
        },
        {
          "id": 215086,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Loss of SNRPN gene </span></span></span></p>"
        },
        {
          "id": 215087,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inherited in autosomal dominant pattern </span></span></span></p>"
        },
        {
          "id": 215088,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduced Ghrelin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is true regarding Prader Willi Syndrome (PWS)?</span></span></p>",
      "unique_key": "Q5102124",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368699,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Loss of SNRPN gene</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prader-Willi Syndrome (PWS) is caused by the lack of expression of paternal genes in the 15q11-q13 region on chromosome 15. The SNRPN gene is a key imprinted gene in this region and its loss of expression contributes to the features of PWS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Most common mechanism of imprinting center mutations:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While imprinting center mutations can cause PWS, the <em><u>most common mechanism is a deletion</u></em> of the paternal 15q11-q13 region (about 70% of cases). 25% cases are due to maternal uniparental disomy and &lt; 1% cases are due to imprinting center mutations. <em><u>FISH is the 1<sup>st</sup> line diagnostic test</u></em> in PWS. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inherited in autosomal dominant pattern:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Most cases of PWS are <em><u>sporadic</u></em> and do not show Mendelian inheritance. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Reduced Ghrelin:&nbsp;</span></strong><span style=\"font-size:12.0pt\"><em><u>Ghrelin levels are actually elevated</u></em> in individuals with PWS, contributing to their hyperphagia and obesity. Patients with PWS also show <em><u>reduced BDNF</u></em> expression, contributing to hyperphagia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prader-Willi syndrome is primarily caused by the loss of the SNRPN gene, leading to hyperphagia and obesity.</span></span></span></p>",
      "correct_choice_id": 215086,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53856,
      "choices": [
        {
          "id": 214897,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Desmopressin (DDAVP) </span></span></span></p>"
        },
        {
          "id": 214898,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thiazides </span></span></span></p>"
        },
        {
          "id": 214899,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fluid restriction </span></span></span></p>"
        },
        {
          "id": 214900,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoids</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old female with a history of psychiatric illness presents with polyuria and polydipsia. A 24-hour urine collection reveals a volume of 4 liters with an osmolality of 200 mOsm/L. Basal plasma ADH is 1.4 pg/mL. Which of the following is the best treatment?</span></span></p>",
      "unique_key": "Q8254692",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368732,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Thiazides</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s clinical presentation, with polyuria, polydipsia, dilute urine and increased ADH (&gt; 1 pg/mL) suggests a diagnosis of nephrogenic diabetes insipidus (NDI). In NDI, use of thiazides (&plusmn; Indomethacin) improves ADH sensitivity and hence, the preferred treatment. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Desmopressin (DDAVP):</span></strong><span style=\"font-size:12.0pt\"> This is a synthetic analog of ADH and is used to treat central DI, where there is a deficiency of ADH. It would not be effective for NDI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Fluid restriction:</span></strong><span style=\"font-size:12.0pt\"> Can treat SIADH but can worsen hypernatremia in NDI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Glucocorticoids:</span></strong><span style=\"font-size:12.0pt\"> Glucocorticoids are not indicated for the treatment of DI (can worsen DI by reducing ADH release)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thiazides are the preferred treatment for nephrogenic diabetes insipidus (NDI) as they improve ADH sensitivity and reduce polyuria.</span></span></p>",
      "correct_choice_id": 214898,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19982,
      "choices": [
        {
          "id": 79889,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA1c </span></span></span></p>"
        },
        {
          "id": 79890,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral glucose tolerance test </span></span></span></p>"
        },
        {
          "id": 79891,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Plasma C-peptide level</span></span></span></p>"
        },
        {
          "id": 79892,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Random plasma glucose level</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 37-year-old obese woman presents to the clinic for a routine health evaluation. She frequently feels thirsty and wakes up at night to urinate. Which of the following studies is the most appropriate first test in evaluating this patient for diabetes mellitus?</span></span></p>",
      "unique_key": "Q8462291",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368697,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Random plasma glucose level</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s symptoms of thirst, polyuria, and recurrent yeast infections raise strong suspicion for diabetes mellitus. Given these symptoms, a random plasma glucose test is the most appropriate initial test. A random plasma glucose level of &gt;200 mg/dL, along with her symptoms, would be diagnostic of diabetes mellitus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hemoglobin A1c:</span></strong><span style=\"font-size:12.0pt\"> While HbA1c is a valuable test for assessing long-term glycemic control, it is not the initial test of choice in a symptomatic patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Oral glucose tolerance test (OGTT):</span></strong><span style=\"font-size:12.0pt\"> OGTT is another diagnostic test for diabetes, but it is more time-consuming and not necessary if the random plasma glucose is diagnostic.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Plasma C-peptide level:</span></strong><span style=\"font-size:12.0pt\"> C-peptide is a marker of endogenous insulin production and is useful in distinguishing between type 1 and type 2 diabetes or evaluating hypoglycemia. It is not the first-line test for diagnosing diabetes in a symptomatic patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Random plasma glucose level is the most appropriate first test for evaluating a symptomatic patient for diabetes mellitus.</span></span></span></p>",
      "correct_choice_id": 79892,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53825,
      "choices": [
        {
          "id": 214773,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyposmia</span></span></span></p>"
        },
        {
          "id": 214774,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypogonadism </span></span></span></p>"
        },
        {
          "id": 214775,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mirror movements</span></span></span></p>"
        },
        {
          "id": 214776,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperacusis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following clinical features is uncommon in Kallmann syndrome?</span></span></p>",
      "unique_key": "Q9024110",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368714,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Hyperacusis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Kallmann syndrome is a genetic disorder (usually due to KAL mutations, X-linked) and is characterized by GnRH deficiency and hyposmia/anosmia due to olfactory bulb hypoplasia or agenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Classically, the syndrome may also be associated with color blindness, optic atrophy, SNHL, cleft palate, renal abnormalities, cryptorchidism, and neurologic abnormalities such as mirror movements (mirror movements can also be seen in cerebral palsy, CVJ anomalies, ALS, Friedrich ataxia and phenylketonuria)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hyposmia or anosmia:</span></strong><span style=\"font-size:12.0pt\"> This is a hallmark feature of Kallmann syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hypogonadism:</span></strong><span style=\"font-size:12.0pt\"> This is the primary hormonal manifestation of Kallmann syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Mirror movements (bimanual synkinesis):</span></strong><span style=\"font-size:12.0pt\"> This is a relatively common associated feature in Kallmann syndrome, although not always present.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperacusis is uncommon in Kallmann syndrome, which primarily features hypogonadism and hyposmia/anosmia.</span></span></span></p>",
      "correct_choice_id": 214776,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53815,
      "choices": [
        {
          "id": 214733,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thyroid hormone controls </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 25% of basal metabolic rate</span></span></span></p>"
        },
        {
          "id": 214734,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aldosterone exerts a permissive action on other hormones. </span></span></span></p>"
        },
        {
          "id": 214735,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Parathyroid hormone (PTH) is a key regulator of calcium and phosphorus homeostasis. </span></span></span></p>"
        },
        {
          "id": 214736,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vasopressin (ADH) is involved in the control of serum osmolality.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is false?</span></span></p>",
      "unique_key": "Q8156990",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368710,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Aldosterone exerts a permissive action on other hormones.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Aldosterone</span></strong><span style=\"font-size:12.0pt\"> is a mineralocorticoid hormone primarily responsible for regulating sodium and potassium balance, which indirectly influences blood pressure and fluid volume. On the other hand, Cortisol exerts a permissive action, which is the ability of one hormone to enhance the responsiveness of a target organ to another hormone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Thyroid hormone:</span></strong><span style=\"font-size:12.0pt\"> Correct. Thyroid hormone does play a significant role in regulating basal metabolic rate, affecting energy expenditure and heat production. It controls </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\">25% of BMR in most tissues. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Parathyroid hormone (PTH):</span></strong><span style=\"font-size:12.0pt\"> Correct. PTH is the primary regulator of calcium and phosphorus homeostasis, acting on bone, kidney, and intestine to maintain normal levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Vasopressin (antidiuretic hormone):</span></strong><span style=\"font-size:12.0pt\"> Correct. Vasopressin regulates serum osmolality by controlling water reabsorption in the kidneys, thus maintaining fluid balance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aldosterone does not exert a permissive action on other hormones; this function is primarily attributed to cortisol.</span></span></span></p>",
      "correct_choice_id": 214734,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}